Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prothena Corporation plc

https://www.prothena.com/

Latest From Prothena Corporation plc

Prothena Gives Amyloidosis Drug Birtamimab A Second Chance

With post hoc analysis from a 2018 study showing a survival benefit in patients at high risk for early mortality, Prothena negotiated a path forward with the US FDA for approval in AL amyloidosis.

Clinical Trials Drug Approval Standards

Prothena Sees Potential In Targeting Amyloid, Validated By Biogen

Prothena views potential approval of Biogen’s aducanumab as a flag in the sand for next-generation amyloid-targeting therapies to race past, including the firm’s own antibody and vaccine programs. 

Research and Development Strategies Neurology

Roche's pRED Leaders On Its Next Generation Of Drugs

"We're not resting on our laurels," pRED head William Pao said in an early R&D overview. The company's R&D leaders highlighted drugs in oncology, neuroscience and ophthalmology.

Research & Development Neurology

Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases

Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Neotope Biosciences Limited
UsernamePublicRestriction

Register